Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.

Jagadeesh, Deepa; Majhail, Navneet S; He, Yizeng; Ahn, Kwang W; Litovich, Carlos; Ahmed, Sairah; Aljurf, Mahmoud; Bacher, Ulrike; Badawy, Sherif M; Bejanyan, Nelli; Cairo, Mitchell; Cerny, Jan; Epperla, Narendranath; Farhadfar, Nosha; Freytes, César O; Gale, Robert Peter; Haverkos, Bradley; Hossain, Nasheed; Inwards, David; Kamble, Rammurti T; ... (2020). Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 126(10), pp. 2279-2287. John Wiley & Sons 10.1002/cncr.32752

[img] Text
Outcoms.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (267kB) | Request a copy

BACKGROUND Although rituximab-based high-dose therapy is frequently used in diffuse large B cell lymphoma (DLBCL) patients undergoing autologous hematopoietic cell transplantation (auto-HCT), data supporting the benefits are not available. Herein, we report the impact of rituximab-based conditioning on auto-HCT outcomes in patients who have DLBCL. METHODS Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, 862 adult DLBCL patients undergoing auto-HCT between 2003 and 2017 using BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning regimen were included. All patients received frontline rituximab-containing chemoimmunotherapy and had chemosensitive disease pre-HCT. Early chemoimmunotherapy failure was defined as not achieving complete remission (CR) after frontline chemoimmunotherapy or relapse within 1 year of initial diagnosis. The primary outcome was overall survival (OS). RESULTS The study cohort was divided into 2 groups: BEAM (n = 667) and R-BEAM (n = 195). On multivariate analysis, no significant difference was seen in OS (P = .83) or progression-free survival (PFS) (P = .61) across the 2 cohorts. No significant association between the use of rituximab and risk of relapse (P = .15) or nonrelapse mortality (P = .12) was observed. Variables independently associated with lower OS included older age at auto-HCT (P < .001), absence of CR at auto-HCT (P < .001) and early chemoimmunotherapy failure (P < .001). Older age (P < .0002) and non-CR pre-HCT (P < .0001) were also associated with inferior PFS. There was no significant difference in early infectious complications between the 2 cohorts. CONCLUSION In this large registry analysis of DLBCL patients undergoing auto-HCT, the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes. Older age, absence of CR pre auto-HCT, and early chemoimmunotherapy failure were associated with inferior survival.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike


600 Technology > 610 Medicine & health




John Wiley & Sons




Pierrette Durand Lüthi

Date Deposited:

15 Jun 2020 10:28

Last Modified:

15 Jun 2020 10:28

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

BEAM autologous transplantation chemoimmunotherapy diffuse large B cell lymphoma rituximab





Actions (login required)

Edit item Edit item
Provide Feedback